Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
  • WIIM
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Downgrades

Downgrades

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Analyst Ratings
  • Downgrades
  • News
  • Price Target

HSBC Downgrades TDCX to Hold, Announces $13 Price Target

By Benzinga Newsdesk
March 8, 7:45 AM
HSBC analyst Shuo Han Tan downgrades TDCX (NYSE:TDCX) from Buy to Hold and announces $13 price target.

TDCX

Read More
1 minute read
  • Analyst Ratings
  • Downgrades
  • News
  • Price Target

Wells Fargo Downgrades Edwards Lifesciences to Equal-Weight, Lowers Price Target to $78

By Benzinga Newsdesk
March 8, 7:02 AM
Wells Fargo analyst Larry Biegelsen downgrades Edwards Lifesciences (NYSE:EW) from Overweight to Equal-Weight and lowers the price target from $97 to $78.

EW

Read More
1 minute read
  • Analyst Ratings
  • Downgrades
  • News
  • Price Target

Berenberg Downgrades Tesla to Hold, Raises Price Target to $210

By Benzinga Newsdesk
March 8, 5:50 AM
Berenberg analyst Adrian Yanoshik downgrades Tesla (NASDAQ:TSLA) from Buy to Hold and raises the price target from $200 to $210.

TSLA

Read More
1 minute read
  • Analyst Ratings
  • Downgrades
  • News
  • Price Target

Keefe, Bruyette & Woods Downgrades Ares Comml Real Est to Market Perform, Announces $12.5 Price Target

By Benzinga Newsdesk
March 8, 5:46 AM
Keefe, Bruyette & Woods analyst Jade Rahmani downgrades Ares Comml Real Est (NYSE:ACRE) from Outperform to Market Perform and announces $12.5 price target.

ACRE

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • Downgrades
  • General
  • Health Care
  • Large Cap
  • News
  • Penny Stocks
  • Reiteration

Analyst Downgrades Gossamer Bio As Merck’s Sotatercept Might Overshadow Seralutinib’s Success

By Vandana Singh
March 7, 2:37 PM
Raymond James has downgraded Gossamer Bio Inc (NASDAQ:GOSS) to Market Perform from Outperform following the publication of sotatercept’s Phase 3 data in NEJM. …

GOSS

Read More
1 minute read
  • Analyst Ratings
  • Downgrades
  • News
  • Price Target

RBC Capital Downgrades Secure Energy Services to Sector Perform, Lowers Price Target to C$8

By Benzinga Newsdesk
March 7, 8:42 AM
RBC Capital analyst Keith Mackey downgrades Secure Energy Services (TSX:SES) from Outperform to Sector Perform and lowers the price target from C$11 to C$8.

TSX:SES

Read More
1 minute read
  • Analyst Ratings
  • Downgrades
  • News
  • Price Target

Baird Downgrades Embark Technology to Neutral, Lowers Price Target to $3

By Benzinga Newsdesk
March 7, 8:21 AM
Baird analyst Ben Kallo downgrades Embark Technology (NASDAQ:EMBK) from Outperform to Neutral and lowers the price target from $15 to $3.

EMBK

Read More
1 minute read
  • Analyst Ratings
  • Downgrades
  • News

HC Wainwright & Co. Downgrades Aptinyx to Neutral

By Benzinga Newsdesk
March 7, 7:17 AM
HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Aptinyx (NASDAQ:APTX) from Buy to Neutral.

APTX

Read More
1 minute read
  • Analyst Ratings
  • Downgrades
  • News

HC Wainwright & Co. Downgrades TCR2 Therapeutics to Neutral

By Benzinga Newsdesk
March 7, 7:13 AM
HC Wainwright & Co. analyst Robert Burns downgrades TCR2 Therapeutics (NASDAQ:TCRR) from Buy to Neutral.

TCRR

Read More
1 minute read
  • Analyst Ratings
  • Downgrades
  • News
  • Price Target

BMO Capital Downgrades Ovintiv to Market Perform, Lowers Price Target to $51

By Benzinga Newsdesk
March 7, 7:03 AM
BMO Capital analyst Phillip Jungwirth downgrades Ovintiv (NYSE:OVV) from Outperform to Market Perform and lowers the price target from $56 to $51.

OVV

Posts navigation

Previous 1 … 7 8 9 … 560 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service